Re-Vana Therapeutics

Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery technologies for the treatment of serious retinal diseases.

Its biodegradable hydrogel platform uses photo-crosslinking to form in-situ implants administered via intravitreal injection, enabling controlled release of biologics, peptides, and small molecules for up to twelve months.

Target indications include age-related macular degeneration, diabetic retinopathy, and glaucoma.

The technology is also being evaluated through partnerships with global pharmaceutical companies.